mRNA future

welcome to today's talk, Tuesday June 11, now that mRNA vaccines are expanding around the world, several plants have been built to produce them, so let's take a look at where we are globally, all the issues that have been raised, the concerns that adverse reactions um don't really seem to have been taken into full awareness and um that are moving forward let me give you some examples here let's start with this this is from madna herself now this is the website that I'm from put the references, of course, as always, from madna madna we get the FDA approval for the RSV vaccine now, what is this vaccine, it's uh, it was May 31, 2024, madna announced today that the Food and Drug Administration from the US, FDA, approved it, so it's called that's the name of the vaccine that they're using there or the genetic uh genetic sequence that they're administering and as we see, it's an mRNA vaccine, acid vaccine ribonucleic messenger, now approved as a second vaccine now when an intramuscular injection is given in the deltoid, the very small particles of lipid nanoparticles, some of them will stay there, but others will return to the systemic circulation, drain into the veins and eventually drain into the venne Caba, which will return to the right side of the heart which will pump the blood to the lungs the lungs the blood will return from the lungs in the pulmonary veins to the left side of the heart in the aorta the left ventricle will pump the blood into the aorta and the The aort it will take it everywhere except the lung tissue, so it will take it to the ears, it will take it to the nose, it will take the blood to the toes, it will take it to the myocardium, it will take it. your brain will take it to your testicles or ovaries.

This is the concern for systemic distribution, but it has now been approved by the FDA for the common respiratory sensitive virus to protect adults aged 60 years and older from lower respiratory tract diseases caused. by respir respir sensial Virus infection um some people might think that the risk from the vaccine is greater than that caused by RSV in older people. This is what the uh press release says. The approval was granted under a breakthrough therapy designation, making it a breakthrough therapy designation and marks the second approved mRNA product for madna, of course, following the CEO approval of madna's covid vaccines by the FDA of our second product.

It relies on the strength and versatility of our mRNA platform and this is true, the mRNA platform is remarkably versatile. Chain any sequence you want to do pretty well what you want and inject it into the human body, but another main concern I have is that in addition to systemic distribution, this is going to potentially every cell in the body, so let's imagine. that this, for example, is a cell that covers the vascular endothelium of the myocardium, the blood that passes through the myocardium, these squamous cells and then comes the lipid nanoparticle that sends the r to the cell, the genetic apparatus of the cell. then make the antigen now when you give an mRNA vaccine you might make a little bit of antigen or you might make a lot of antigen.

As far as I know, the dose of RNA you give him is not as good as he makes it out to be. The amount of antigen that is produced is not determined, so a little or a lot can be produced, and to me this goes against one of the completely fundamental axioms of giving medications: you give the right dose of the right drug in the right time. patient at the right time through the right route how do you know the dose? Because there's no telling how much antigen the body is going to produce anyway. Going back to the diagram, the cells here will produce the antigen, whatever it is now. that's on your arm and some white blood cells appear, let's say, some cytotoxic tea cells and these cytotoxic tea cells, if they recognize this antigen as foreign and they'll start hitting it and probably eventually could kill it completely. cell actually um now if that's in your arm your arm hurts if it's in your myocardium you'll have inflammation in your myocardium so the spike protein was particularly pathogenic very strange that the spike protein was chosen very, very strange in My point of view, but any antigen that reaches the surface of the cells will be recognized by the immune system, the inflammatory reaction will be there, the immune system will attack these cells thinking that these cells are virally infected and will kill them, and this concern so far . as I know it has not been addressed and yet the program is moving forward at a pace so that is my concern, the systemic distribution and production of unknown or undetermined amounts of antigen and the reaction of the immune cell to the expressed antigen by the body's cells, of course, this might not be a cell, these cells might not be in the myocardium, um, they might be in the testicles or the ovaries, you see why I'm worried anyway, let's move on, that was that ad. a little bit more about that um Mna hopes to have this uh irsv vaccine available to eligible populations in the United States for the 2024 2025 respiratory virus season, which of course is next winter, madna has filed Mr approval with regulators in multiple markets around the world, so I don't know, but I mean we can assume this includes the UK.

I think we can assume it includes Australia, Canada, New Zealand, in fact I assume it includes anyone who can pay. I won't get one. Let's move on. to another area here uh this is from uh clinical trials Arena now here is the uh here is the announcement about this take a look this is not me making it up all the information is there for your reading now Madna advances in the flu and covid -19 vaccine race combined with phase three win um win okay he called it a victory uh now this is called madna shot Mr. again messenger ribonucleic acid so in addition to RSV we are now getting this flu switching to mRNA now of course Yeah. they have existing flu vaccines but they want to replace them with these new genetic sequence vaccines, let's see, it seems to be the way that progress is being facilitated now, this Mr.

Mr. uh 1083 uh comprises a seasonal flu vaccine, so which contains an influenza vaccine and this is the mRNA uh 1010 is the mRNA influenza vaccine, so again the RNA will encode a sequence and the body's own cells will produce it by expressing it on their surfaces and of course another concern is um and we haven't heard that this has been fully addressed. normally M, normally it is RN, sorry, DNA, deoxyribonucleic acid, produces RNA, produces a protein called central dogma and DNA becomes RNA, which will be called transcription and this RNA into protein will be called translation if RNA returns the information to DNA that would be called reverse transcription and we know that there are enzymes in the body called reverse transcriptase, let's hope that doesn't happen and the next one so it contains this is this is the flu vaccine here and this is the new uh what are they? they call it Prospect next generation covid-19 vaccine and that's the new uh covid vaccine so it's a combination of influenza RNA and uh Co RNA so this would be giving two RNA vaccines to the same person in the same syringe, same syringe in the same injection site now, this is not me making this up honestly look at these references that I have given you and see for yourself um, it's all there I know you may be struggling with credulity and belief, but I'm just reporting what it is About these references that I'm giving you, Madna announces positive data from a phase three trial of its vaccine candidate Mr. uh, now in the phase three trial, these trials phase three, that's the trial that seems to be ongoing, crazy, it says statistically significant higher. immune response compared to existing vaccines on the market, the trial met its preliminary endpoints as published in the June 10 press release immune response re SE in three strains of influenza, so it appears that this encodes three strains of influenza H1N1 H3N2, these are different strains of influenza and B Victoria, so three different types of influenza s Tri veent, so presumably it contains three types of RNA.

I don't know, presumably yes and the covid spike protein, assuming they are still using the RNA spike protein, all in one injection, although madna has not published the full data from the phase 3 trials, but plans to present the results in more detail at an upcoming medical conference. Okay, next medical conference, in addition to filing for publication, the company said it will collaborate with regulators on the next step. looks like it's coming to a regulator near you right now it's not just this there are other RN vaccines in the pipeline let me tell you this this is from this info here madna advances multiple vaccine programs into late stage clinical trials its March 27, 2024 press release, so cyto megala virus is a pivotal EP phase 3 trial evaluating this is cyto megala virus mRNA, so again presumably encoding cyto megala virus, some of the epitopes of the cyto megagala virus antigens in cegala.

A very common virus doesn't cause problems most of the time, but to be fair, it can cause problems for children if they catch it from their mother. Epin bar virus um now this is the virus that causes infectious mononucleosis uh moncle fever um um GL which can be a very unpleasant infection in adults but of course virtually everyone has been exposed to it probably 95 % of the population already has antibodies against it. The randomized, observer-blind, placebo-controlled study is fully enrolled, so it looks like this, uh, EBV Epstein virus. the trial is ready to go herp just another mRNA vaccine phase one two trials right now zoster rod this would be for shingles mainly I guess mRNA 1468 as initial data available from a phase one two Norv vad virus that gives you watery diarrhea During a few days another mRNA vaccine is being actively developed, as far as I know the British government has a deal with Madna last time I checked just for a billion pounds.

I think we have agreed to purchase these vaccines during the next. 10 years the same in Australia they are building huge new mRNA plants, the same in Canada. It seems like mRNA will be the

future

, right? Needless to say, I will not be signing up for any of these trials. I will not accept any of these vaccines, but that is what is happening. They are being developed on a totally enormous scale and the FDA has already approved one more. They are approaching regulators around the world. It's pretty incredible, but it's underway. Just think of all the people we've interviewed on this channel with vaccine injuries. and yet, in my opinion, all of this is going ahead without adequately addressing security issues.

It's pretty incredible, but the regulators are there to protect us, I hope they do. I mean, they are largely funded by the pharmaceutical industry, but I'm sure that won't influence their decision. - I'm not doing anything more than saying, I really mean I'm just giving you this information um yeah, that's an interesting

future

ahead, thanks for watching.